Chondrosarcoma Foundation Think Tank Meeting
Chondrosarcoma Foundation Think Tank
Topic 5: Research and Clinical Trials
On November 11 in Boca Raton, Florida; the Chondrosarcoma Foundation hosted its first Think Tank entitled: Advancing Chondrosarcoma Treatment, Preventing Disease Progression, Recurrence & Metastasis. The link to this video is: https://csfshayna.org/research/
This session addresses the status of chondrosarcoma research, clinical trials, and recommendations for innovative studies to prevent recurrence and metastasis. The role of IDH1 is examined as well as the difference between IDH1 mutated and nonmutated tumors and the progression genomically and epigenetically for both. An overview of current clinical trials including INBRX 109, Ivosidenib, SON1010+Trabectedin and DNG64 (formerly DeltaRex-G) and the role they have in the prevention of disease progression. A look at what innovative, science-based interventions can work towards preventing disease progression and address aggressive sub-types and advanced metastatic chondrosarcoma and how we advance discovering new molecular targets for treatment, identify novel approaches to combat drug resistance to existing treatments and identify biomarkers as a tool for earlier detection and prevention of disease progression?
Sant Chawla, M.D. is the Chief Medical Director of Sarcoma Oncology Research Center in Santa Monica, CA.He provides an overview of the drugs being used to treat chondrosarcoma as well as potential for other medications including DNG64 (formerly DeltaRex-G).
William Cross, Ph.D., is the Director Rare Malignancies and Cancer Evolution laboratory at Reading University in Reading, UK. In his absence, he presented a Short Video on his current research on biomarkers including IDH and TERT for Chondrosarcoma and implications that biomarkers change with disease progression.
Jonathan C. Trent, M.D., is the Associate Director of Clinical Research and Director of the Bone and Soft-tissue Sarcoma Group, for the Sylvester Cancer Center, University of Miami in Miami, FL. He presented an overview on IDH and his research and its role in inhibiting disease progression.
Kenneth Rankin, M.B.Ch.B., M.D., is an Orthopedic Surgeon and a Translational and Clinical Researcher for the Newcastle University Centre for Cancer in Newcastle upon Tyre, UK. Dr. Rankin introduced a new innovative technique involving an intravenous injection of Indocyanine Green and the use of a Flourescence camera to identify all the existing tumor during surgery.
